Company Overview and News


Add PAR
to your dashboard

Headline News

Paradigm Biopharmaceuticals granted European patent

2018-01-15 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has been granted a European patent for the treatment of bone marrow edema lesions with the drug pentosan polysulfate sodium (PPS).

Paradigm Biopharmaceuticals meets primary endpoint in clinical trial

2017-11-14 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has received results from its phase 2a clinical trial in bone marrow lesions (bone bruising) as a result of an anterior cruciate ligament (ACL) injury.

Paradigm Biopharmaceuticals funded into 2019 through placement

2017-11-06 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has completed a share placement to raise $5.75 million by issuing shares priced at $0.30 to institutional, sophisticated and professional investors.

Paradigm Biopharmaceuticals to finalise raising

2017-11-01 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) remains focused on repurposing pentosan polysulfate sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation.

Paradigm has successfully dosed first participant in clinical trial for osteoarthritis

2017-10-30 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has now dosed the first participant in the Phase 2b clinical trial at Emeritus Research in Malvern East, Victoria.

Paradigm reveals outcomes from patient case studies on Osteoarthritis

2017-10-11 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has outlined the results of 24 patient case studies with Osteoarthritis (OA) and Bone Marrow Edema Lesions (BMELs) that were treated with Pentosan Polysulfate Sodium (PPS) under the Therapeutic Goods Administration’s (TGA) Special Access Scheme.

Paradigm Biopharmaceuticals receives ethics approval for trial on knee osteoarthritis

2017-09-20 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received ethics approval for its Phase 2b clinical trial to investigate Pentosan Polysulfate Sodium (PPS) in subjects with knee osteoarthritis (OA) and bone marrow edema lesions (BMELs).

Paradigm Biopharmaceuticals shares continue uptrend on leverage to Pentosan Polysulfate Sodium

2017-09-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has added another 2% to $0.40 in early trade, after jumping 40% yesterday, following a peer-reviewed publication.

Paradigm Biopharmaceuticals shares jump 75% in morning trade

2017-09-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has caught investor attention this morning with its shares jumping 75% following the publication of a peer-reviewed journal of the potential of Pentosan Polysulfate Sodium (PPS).

Paradigm's Paul Rennie discusses momentum of the Ross River Virus Clinical Trial

2017-09-14 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) continues to advance its Phase 2 Ross River Virus Clinical Trial, with 25% of the 24-participant total having now been dosed across the initial two trial sites in Geelong and Brisbane.

Paradigm Biopharmaceuticals doses first Ross River participant

2017-08-09 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has successfully dosed its first participant in its Phase 2 Alphavirus clinical trial of the drug pentosan polysulfate sodium (PPS) for the treatment of Ross River virus.

Paradigm Biopharmaceuticals Ltd to commence Ross River trial

2017-07-10 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is now ready to commence its Phase 2 Alphavirus clinical trial of the drug pentosan polysulfate sodium (PPS) for the treatment of Ross River virus.

Paradigm Biopharmaceuticals CEO lifts stake over 22%

2017-06-28 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, is a major shareholder in the company and on-market purchases have lifted him to a 22.06% stake.

Paradigm Biopharmaceuticals CEO buys shares on-market

2017-06-26 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has received a vote of confidence from its CEO and director, Paul Rennie, who has purchased $100,618.95 worth of shares on-market.

Paradigm Biopharmaceuticals enters US$18 billion global heart failure market

2017-06-20 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has expanded its drug development pipeline by in-licensing Pentosan Polysulfate Sodium (PPS) for the treatment of heart failure from the University of Oslo, Norway.